
Bavarian Nordic raised its expectations for the full year on Friday last week, a consequence of the vaccine firm signing a contract with the US government concerning half a million doses of monkeypox vaccine Jynneos.
This is nothing short of the third guidance upgrade in the span of a few weeks that the firm has announced subsequent to landing a deal. However, despite now having a clearer view of upcoming orders, Bavarian has decided not to include expected orders into its prognosis, Head of Investor Relations at Bavarian Rolf Sass Sørensen tells MarketWire.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app